We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Gene Therapy Successfully Treats SCID

By Biotechdaily staff writers
Posted on 23 May 2002
An infant suffering from X chromosome-linked severe combined immunodeficiency disorder (SCID) that made him too weak to even hold his head up has been restored to a normal life at home following gene therapy.

Before the therapy, the infant was confined to a sterile space and kept alive by a ventilator. More...
A victim of SCID is often called "baby in a bubble” because of the plastic shroud used to preserve sterile conditions around the patient and prevent infection. Standard treatment is a bone marrow transplant but the infant's parents chose the new treatment of gene therapy, in part to obviate the need for chemotherapy, which accompanies bone marrow transplantation.

Doctors took stem cells from the infant's bone marrow and froze them. A bag of the cells was connected to a bag containing a mouse retrovirus genetically engineered to carry a healthy copy of the defective gene in the infant. The virus spliced the good gene into the stem cells and these were reinserted into the infant's bone. Within several months, the infant's lymphocyte count began a rapid rise. Doctors say the infant will need to be followed for many years.

"We're very pleased to announce the first successful cure of a patient in the United Kingdom by gene therapy,” said Professor Christine Kinnon, director of the Center for Gene Therapy of Childhood Disease at the Institute of Child Health (London), who collaborated with doctors at Great Ormond Street Hospital (London) in administering the treatment.




Related Links:
Institute of Child Health

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Pipette Calibration System
Artel PCS®
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.